Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.

Key facts

Study ID

NCT02472977

Run by

Bristol-Myers Squibb

People needed

61

Starts

2015-07-13

Expected to finish

2017-01-27

Last updated by the study team

2018-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• SCLC or PAC that is advanced or has spread to other parts of the body
• Treated with at least one other chemotherapy that did not work or where cancer relapsed
• Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1

You may not qualify if…

• Patients with cancer that spread to the brain
• Active, known or suspected autoimmune disease
• Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

Where it is running

• University Of Colorado Hosp — Aurora, Colorado, United States
• Indiana University Health — Indianapolis, Indiana, United States
• Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins — Baltimore, Maryland, United States
• Columbia University Medical Center (Cumc) — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Local Institution — Helsinki, Finland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.